Receptor-targeted quantum dots: Fluorescent probes for brain tumor diagnosis

Jingjing Wang, William H. Yong, Yinghua Sun, P. Thomas Vernier, H. Phillip Koeffler, Martin A. Gundersen, Laura Marcu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The intraoperative diagnosis of brain tumors and the timely evaluation of biomarkers that can guide therapy are hindered by the paucity of rapid adjunctive studies. This study evaluates the feasibility and specificity of using quantum dot-labeled antibodies for rapid visualization of epidermal growth factor receptor (EGFR) expression in human brain tumor cells and in surgical frozen section slides of glioma tissue. Streptavidin-coated quantum dots (QDs) were conjugated to anti-EGFR antibodies and incubated with target cultured tumor cells and tissues. The experiments were conducted first in human glioma tumor cell lines with elevated levels of EGFR expression (SKMG-3, U87) and then in frozen tissue sections of glioblastoma multiforme and of oligodendroglioma. The bioconjugated QDs used in the study were found to bind selectively to brain tumor cells expressing EGFR. QD complexed quickly to the cell membrane (less than 15 min), and binding was highly specific and depended on the expression level of EGFR on the cell membrane. Tissue experiments showed that only tumor specimens expressing EGFR were labeled in less than 30 min by QD complexes. These findings demonstrate that QD-labeled antibodies can provide a quick and accurate method for characterizing the presence or absence of a specific predictive biomarker.

Original languageEnglish (US)
Article number044021
JournalJournal of Biomedical Optics
Volume12
Issue number4
DOIs
StatePublished - Jul 2007

Fingerprint

Quantum Dots
Fluorescent Dyes
Epidermal Growth Factor Receptor
Brain Neoplasms
Semiconductor quantum dots
brain
Tumors
Brain
tumors
quantum dots
probes
antibodies
Cells
Antibodies
Tissue
biomarkers
Frozen Sections
Biomarkers
Cell membranes
Glioma

Keywords

  • Brain tumors
  • Epidermal growth factor receptor
  • Fluorescent nanoparticles
  • Gliomas
  • Optical imaging
  • Quantum dots

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials
  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Clinical Biochemistry

Cite this

Wang, J., Yong, W. H., Sun, Y., Vernier, P. T., Koeffler, H. P., Gundersen, M. A., & Marcu, L. (2007). Receptor-targeted quantum dots: Fluorescent probes for brain tumor diagnosis. Journal of Biomedical Optics, 12(4), [044021]. https://doi.org/10.1117/1.2764463

Receptor-targeted quantum dots : Fluorescent probes for brain tumor diagnosis. / Wang, Jingjing; Yong, William H.; Sun, Yinghua; Vernier, P. Thomas; Koeffler, H. Phillip; Gundersen, Martin A.; Marcu, Laura.

In: Journal of Biomedical Optics, Vol. 12, No. 4, 044021, 07.2007.

Research output: Contribution to journalArticle

Wang, J, Yong, WH, Sun, Y, Vernier, PT, Koeffler, HP, Gundersen, MA & Marcu, L 2007, 'Receptor-targeted quantum dots: Fluorescent probes for brain tumor diagnosis', Journal of Biomedical Optics, vol. 12, no. 4, 044021. https://doi.org/10.1117/1.2764463
Wang J, Yong WH, Sun Y, Vernier PT, Koeffler HP, Gundersen MA et al. Receptor-targeted quantum dots: Fluorescent probes for brain tumor diagnosis. Journal of Biomedical Optics. 2007 Jul;12(4). 044021. https://doi.org/10.1117/1.2764463
Wang, Jingjing ; Yong, William H. ; Sun, Yinghua ; Vernier, P. Thomas ; Koeffler, H. Phillip ; Gundersen, Martin A. ; Marcu, Laura. / Receptor-targeted quantum dots : Fluorescent probes for brain tumor diagnosis. In: Journal of Biomedical Optics. 2007 ; Vol. 12, No. 4.
@article{780d922ab1054963b7ce0e262ee987e5,
title = "Receptor-targeted quantum dots: Fluorescent probes for brain tumor diagnosis",
abstract = "The intraoperative diagnosis of brain tumors and the timely evaluation of biomarkers that can guide therapy are hindered by the paucity of rapid adjunctive studies. This study evaluates the feasibility and specificity of using quantum dot-labeled antibodies for rapid visualization of epidermal growth factor receptor (EGFR) expression in human brain tumor cells and in surgical frozen section slides of glioma tissue. Streptavidin-coated quantum dots (QDs) were conjugated to anti-EGFR antibodies and incubated with target cultured tumor cells and tissues. The experiments were conducted first in human glioma tumor cell lines with elevated levels of EGFR expression (SKMG-3, U87) and then in frozen tissue sections of glioblastoma multiforme and of oligodendroglioma. The bioconjugated QDs used in the study were found to bind selectively to brain tumor cells expressing EGFR. QD complexed quickly to the cell membrane (less than 15 min), and binding was highly specific and depended on the expression level of EGFR on the cell membrane. Tissue experiments showed that only tumor specimens expressing EGFR were labeled in less than 30 min by QD complexes. These findings demonstrate that QD-labeled antibodies can provide a quick and accurate method for characterizing the presence or absence of a specific predictive biomarker.",
keywords = "Brain tumors, Epidermal growth factor receptor, Fluorescent nanoparticles, Gliomas, Optical imaging, Quantum dots",
author = "Jingjing Wang and Yong, {William H.} and Yinghua Sun and Vernier, {P. Thomas} and Koeffler, {H. Phillip} and Gundersen, {Martin A.} and Laura Marcu",
year = "2007",
month = "7",
doi = "10.1117/1.2764463",
language = "English (US)",
volume = "12",
journal = "Journal of Biomedical Optics",
issn = "1083-3668",
publisher = "SPIE",
number = "4",

}

TY - JOUR

T1 - Receptor-targeted quantum dots

T2 - Fluorescent probes for brain tumor diagnosis

AU - Wang, Jingjing

AU - Yong, William H.

AU - Sun, Yinghua

AU - Vernier, P. Thomas

AU - Koeffler, H. Phillip

AU - Gundersen, Martin A.

AU - Marcu, Laura

PY - 2007/7

Y1 - 2007/7

N2 - The intraoperative diagnosis of brain tumors and the timely evaluation of biomarkers that can guide therapy are hindered by the paucity of rapid adjunctive studies. This study evaluates the feasibility and specificity of using quantum dot-labeled antibodies for rapid visualization of epidermal growth factor receptor (EGFR) expression in human brain tumor cells and in surgical frozen section slides of glioma tissue. Streptavidin-coated quantum dots (QDs) were conjugated to anti-EGFR antibodies and incubated with target cultured tumor cells and tissues. The experiments were conducted first in human glioma tumor cell lines with elevated levels of EGFR expression (SKMG-3, U87) and then in frozen tissue sections of glioblastoma multiforme and of oligodendroglioma. The bioconjugated QDs used in the study were found to bind selectively to brain tumor cells expressing EGFR. QD complexed quickly to the cell membrane (less than 15 min), and binding was highly specific and depended on the expression level of EGFR on the cell membrane. Tissue experiments showed that only tumor specimens expressing EGFR were labeled in less than 30 min by QD complexes. These findings demonstrate that QD-labeled antibodies can provide a quick and accurate method for characterizing the presence or absence of a specific predictive biomarker.

AB - The intraoperative diagnosis of brain tumors and the timely evaluation of biomarkers that can guide therapy are hindered by the paucity of rapid adjunctive studies. This study evaluates the feasibility and specificity of using quantum dot-labeled antibodies for rapid visualization of epidermal growth factor receptor (EGFR) expression in human brain tumor cells and in surgical frozen section slides of glioma tissue. Streptavidin-coated quantum dots (QDs) were conjugated to anti-EGFR antibodies and incubated with target cultured tumor cells and tissues. The experiments were conducted first in human glioma tumor cell lines with elevated levels of EGFR expression (SKMG-3, U87) and then in frozen tissue sections of glioblastoma multiforme and of oligodendroglioma. The bioconjugated QDs used in the study were found to bind selectively to brain tumor cells expressing EGFR. QD complexed quickly to the cell membrane (less than 15 min), and binding was highly specific and depended on the expression level of EGFR on the cell membrane. Tissue experiments showed that only tumor specimens expressing EGFR were labeled in less than 30 min by QD complexes. These findings demonstrate that QD-labeled antibodies can provide a quick and accurate method for characterizing the presence or absence of a specific predictive biomarker.

KW - Brain tumors

KW - Epidermal growth factor receptor

KW - Fluorescent nanoparticles

KW - Gliomas

KW - Optical imaging

KW - Quantum dots

UR - http://www.scopus.com/inward/record.url?scp=35948956704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948956704&partnerID=8YFLogxK

U2 - 10.1117/1.2764463

DO - 10.1117/1.2764463

M3 - Article

C2 - 17867825

AN - SCOPUS:35948956704

VL - 12

JO - Journal of Biomedical Optics

JF - Journal of Biomedical Optics

SN - 1083-3668

IS - 4

M1 - 044021

ER -